{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T22:09:34Z","timestamp":1744495774327},"reference-count":28,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Up to 20% of women having a cytology smear showing atypical squamous cells of undetermined significance (ASC-US) and infected with high-risk human papillomavirus (HR HPV) have high-grade cervical intraepithelial neoplasia (CIN 2\/3). Results obtained with the Amplicor HPV and Hybrid Capture 2 (HC-2) assays for HR HPV DNA detection in women referred to colposcopy for an ASC-US smear were compared. Cervical samples in PreservCyt were tested for the presence of 13 HR HPV types with HC-2, with Amplicor at three cutoffs for positivity (0.2, 1.0, and 1.5 optical density units), and for 36 genotypes with the Linear Array (LA). Of 396 eligible women, 316 did not have CIN, 47 had CIN 1, 29 had CIN 2\/3, and 4 had CIN of unknown grade. HR HPV was detected in 129 (32.6%) and 164 (41.4%) samples with HC-2 and Amplicor HPV (cutoff, 0.2), respectively (\n            <jats:italic>P<\/jats:italic>\n            = 0.01). Overall, 112 specimens were positive and 215 were negative with the HC-2 and Amplicor HPV assays (agreement of 82.6%; 95% confidence interval [CI], 78.5 to 86.0). The clinical sensitivity and specificity of Amplicor HPV at cutoffs of 0.2, 1.0 and 1.5 and of HC-2 for detection of CIN 2\/3 were 89.7% (95% CI, 72.8 to 97.2) and 62.5% (95% CI, 57.5 to 52.4), 89.7% (95% CI, 72.8 to 97.2) and 64.5% (95% CI, 59.4 to 69.2), 89.7% (95% CI, 72.8 to 97.2) and 64.7% (95% CI, 59.7 to 69.5), and 93.1% (95% CI, 77.0 to 99.2) and 72.2% (95% CI, 67.4 to 76.5), respectively. Both HR HPV detection tests identified women with ASC-US who would benefit the most from colposcopy. Women with persistent HR HPV infection need further investigation despite a first normal colposcopy.\n          <\/jats:p>","DOI":"10.1128\/jcm.01063-10","type":"journal-article","created":{"date-parts":[[2010,11,18]],"date-time":"2010-11-18T03:32:17Z","timestamp":1290051137000},"page":"48-53","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix"],"prefix":"10.1128","volume":"49","author":[{"given":"Simon","family":"Dufresne","sequence":"first","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Sauthier","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-He\u0301le\u0300ne","family":"Mayrand","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Petignat","sequence":"additional","affiliation":[{"name":"Unite\u0301 d'Oncogyne\u0301cologie, Ho\u0302pitaux Universitaires de Gene\u0300ve, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Provencher","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Drouin","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gauthier","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Jose\u0301e","family":"Dupuis","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Michon","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ste\u0301phan","family":"Ouellet","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"Hadjeres","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Ferenczy","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Obstetrics &amp; Gynecology, the Sir Mortimer B. Davis Jewish General Hospital and McGill University, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo L.","family":"Franco","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University, Montreal, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franc\u0327ois","family":"Coutle\u0301e","sequence":"additional","affiliation":[{"name":"De\u0301partements de Microbiologie et Infectiologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Centre Hospitalier de l'Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"De\u0301partements de Microbiologie-Immunologie, de Gyne\u0301cologie-Obste\u0301trique, et de Pathologie, Universite\u0301 de Montre\u0301al, Montre\u0301al, Que\u0301bec, Canada"},{"name":"Division of Cancer Epidemiology, McGill University, Montreal, Que\u0301bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","unstructured":"Bais A. G. et al. 2009. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual\/recurrent disease. Int. J. Cancer. 124 : 889-895.","DOI":"10.1002\/ijc.23824"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","unstructured":"Bosch F. X. A. Lorincz N. Munoz C. J. L. M. Meijer and K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55 : 244-265.","DOI":"10.1136\/jcp.55.4.244"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","unstructured":"Bouvard V. et al. 2009. A review of human carcinogens. Part B. Biological agents. Lancet Oncol. 10 : 321-322.","DOI":"10.1016\/S1470-2045(09)70096-8"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","unstructured":"Carozzi F. et al. 2007. Agreement between the AMPLICOR human papillomavirus test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J. Clin. Microbiol. 45 : 364-369.","DOI":"10.1128\/JCM.00706-06"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","unstructured":"Castle P. E. et al. 2008. Human papillomavirus genotype specificity of hybrid capture 2. J. Clin. Microbiol. 46 : 2595-2604.","DOI":"10.1128\/JCM.00824-08"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","unstructured":"Coutlee F. et al. 2006. Enhanced detection and typing of human papillomavirus DNA in anogenital samples with PGMY primers and the Linear Array HPV genotyping test. J. Clin. Microbiol. 44 : 1998-2006.","DOI":"10.1128\/JCM.00104-06"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Coutlee F. et al. 2007. Confirmatory real-time PCR assay for human papillomavirus (HPV) type 52 infection in anogenital specimens screened for HPV infection with the linear array HPV genotyping test. J. Clin. Microbiol. 45 : 3821-3823.","DOI":"10.1128\/JCM.01145-07"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","unstructured":"Ferenczy A. D. Choukroun and J. Arseneau. 1996. Loop electrosurgical excision procedure for squamous intraepithelial lesions of the cervix: advantages and potential pitfalls. Obstet. Gynecol. 87 : 332-337.","DOI":"10.1016\/0029-7844(95)00453-X"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","unstructured":"Franco E. L. and D. M. Harper. 2005. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 23 : 2388-2394.","DOI":"10.1016\/j.vaccine.2005.01.016"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","unstructured":"Gravitt P. E. et al. 2008. New technologies in cervical cancer screening. Vaccine 26 : K42-K52.","DOI":"10.1016\/j.vaccine.2008.05.002"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","unstructured":"Halfon P. et al. 2007. Prospective evaluation of the Hybrid Capture 2 and AMPLICOR human papillomavirus (HPV) tests for detection of 13 high-risk HPV genotypes in atypical squamous cells of uncertain significance. J. Clin. Microbiol. 45 : 313-316.","DOI":"10.1128\/JCM.00992-06"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","unstructured":"Kim J. J. T. C. Wright and S. J. Goldie. 2002. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287 : 2382-2390.","DOI":"10.1001\/jama.287.18.2382"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","unstructured":"Mayrand M. H. et al. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357 : 1579-1588.","DOI":"10.1056\/NEJMoa071430"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Mo L. Z. et al. 2008. Comparison of AMPLICOR and Hybrid Capture II assays for high risk HPV detection in normal and abnormal liquid-based cytology: use of INNO-LiPA genotyping assay to screen the discordant results. J. Clin. Virol. 41 : 104-110.","DOI":"10.1016\/j.jcv.2007.09.012"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","unstructured":"Monsonego J. et al. 2005. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol. Oncol. 99 : 160-168.","DOI":"10.1016\/j.ygyno.2005.05.030"},{"key":"e_1_3_2_17_2","unstructured":"Poljak M. K. Fujs K. Seme B. J. Kocjan and E. Vrtacnik Bokal. 2005. Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples. Acta Dermatovenerol. Alp. Panonica Adriat. 14 : 147-152."},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Sandri M. T. et al. 2006. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44 : 2141-2146.","DOI":"10.1128\/JCM.00049-06"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","unstructured":"Sargent A. et al. 2010. Optimal threshold for a positive Hybrid Capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J. Clin. Microbiol. 48 : 554-558.","DOI":"10.1128\/JCM.00896-09"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","unstructured":"Sarian L. O. S. F. Derchain D. R. Pitta S. S. Morais and S. H. Rabelo Santos. 2004. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). J. Clin. Virol. 31 : 270-274.","DOI":"10.1016\/j.jcv.2004.05.012"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","unstructured":"Sarian L. O. et al. 2004. HPV DNA test and Pap smear in detection of residual and recurrent disease following loop electrosurgical excision procedure of high-grade cervical intraepithelial neoplasia. Gynecol. Oncol. 94 : 181-186.","DOI":"10.1016\/j.ygyno.2004.03.036"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","unstructured":"Solomon D. M. Schiffman R. Tarone and ALTS Study group. 2001. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J. Natl. Cancer Inst. 93 : 293-299.","DOI":"10.1093\/jnci\/93.4.293"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","unstructured":"Song S. H. et al. 2006. Persistent HPV infection after colonization in patients with negative margins. Gynecol. Oncol. 101 : 418-422.","DOI":"10.1016\/j.ygyno.2005.10.028"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","unstructured":"Stevens M. P. et al. 2007. Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and Linear Array human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol. 45 : 2130-2137.","DOI":"10.1128\/JCM.02438-06"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","unstructured":"Trottier H. and E. L. Franco. 2006. The epidemiology of genital human papillomavirus infection. Vaccine 24 : S1-S15.","DOI":"10.1016\/j.vaccine.2005.09.054"},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","unstructured":"van Ham M. A. et al. 2005. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J. Clin. Microbiol. 43 : 2662-2667.","DOI":"10.1128\/JCM.43.6.2662-2667.2005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","unstructured":"Wahlstrom C. T. Iftner J. Dillner and L. Dillner. 2007. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J. Med. Virol. 79 : 1169-1175.","DOI":"10.1002\/jmv.20898"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Wentzensen N. P. E. Gravitt D. Solomon C. M. Wheeler and P. E. Castle. 2009. A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. Cancer Epidemiol. Biomarkers Prev. 18 : 1341-1349.","DOI":"10.1158\/1055-9965.EPI-08-1180"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","unstructured":"Wright T. C. J. et al. 2007. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197 : 346-355.","DOI":"10.1016\/j.ajog.2007.07.047"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01063-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.01063-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T12:45:51Z","timestamp":1646484351000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.01063-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1128\/JCM.01063-10"],"URL":"https:\/\/doi.org\/10.1128\/jcm.01063-10","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"2010-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-01-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}